MA23441A1 - Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88". - Google Patents

Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88".

Info

Publication number
MA23441A1
MA23441A1 MA23768A MA23768A MA23441A1 MA 23441 A1 MA23441 A1 MA 23441A1 MA 23768 A MA23768 A MA 23768A MA 23768 A MA23768 A MA 23768A MA 23441 A1 MA23441 A1 MA 23441A1
Authority
MA
Morocco
Prior art keywords
irp
paroxetine
formulation including
new formulation
amberlite
Prior art date
Application number
MA23768A
Other languages
English (en)
Inventor
Cooper David
Stanley Leonard Graham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA23441A1 publication Critical patent/MA23441A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA23768A 1994-02-03 1995-02-01 Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88". MA23441A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation

Publications (1)

Publication Number Publication Date
MA23441A1 true MA23441A1 (fr) 1995-10-01

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23768A MA23441A1 (fr) 1994-02-03 1995-02-01 Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88".

Country Status (33)

Country Link
US (1) US5811436A (fr)
EP (1) EP0742715B1 (fr)
JP (1) JP4445590B2 (fr)
CN (1) CN1074922C (fr)
AP (2) AP611A (fr)
AT (1) ATE178489T1 (fr)
AU (1) AU682091B2 (fr)
BG (1) BG62843B1 (fr)
BR (1) BR9507055A (fr)
CA (1) CA2182593A1 (fr)
CZ (1) CZ285128B6 (fr)
DE (1) DE69508924T2 (fr)
DK (1) DK0742715T3 (fr)
DZ (1) DZ1850A1 (fr)
ES (1) ES2129806T3 (fr)
FI (1) FI118205B (fr)
GB (1) GB9402029D0 (fr)
GR (1) GR3030131T3 (fr)
HU (1) HUT75941A (fr)
IL (1) IL112521A (fr)
MA (1) MA23441A1 (fr)
MX (1) MX9603203A (fr)
MY (1) MY113036A (fr)
NO (1) NO307954B1 (fr)
NZ (1) NZ278891A (fr)
OA (1) OA10446A (fr)
PL (1) PL178331B1 (fr)
RO (1) RO116342B1 (fr)
RU (1) RU2136281C1 (fr)
SK (1) SK281214B6 (fr)
TW (1) TW436296B (fr)
WO (1) WO1995020964A1 (fr)
ZA (1) ZA95776B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EE03970B1 (et) 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
WO2003013470A1 (fr) * 2001-08-09 2003-02-20 Smithkline Beecham Plc. Composition comprenant de la paroxetine et un sel de glycyrrhizinate pharmaceutiquement acceptable
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
WO2007058998A2 (fr) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科(北京)研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
WO2010150219A1 (fr) * 2009-06-25 2010-12-29 Wockhardt Research Centre Composition pharmaceutique de duloxétine ou ses sels pharmaceutiquement acceptables
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
PH12012502132A1 (en) 2010-05-19 2013-02-04 Astellas Pharma Inc Pharmaceutical composition containing solifenacin
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
ES2991429T3 (es) 2019-02-01 2024-12-03 Univ South Carolina Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
GB2636182A (en) 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (fr) * 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Also Published As

Publication number Publication date
CN1140411A (zh) 1997-01-15
PL178331B1 (pl) 2000-04-28
DZ1850A1 (fr) 2002-02-17
HU9602151D0 (en) 1996-09-30
BG100763A (bg) 1997-03-31
MX9603203A (es) 1997-03-29
NZ278891A (en) 1998-01-26
AU682091B2 (en) 1997-09-18
DE69508924D1 (de) 1999-05-12
IL112521A0 (en) 1995-05-26
BR9507055A (pt) 1997-09-02
AU1536895A (en) 1995-08-21
EP0742715B1 (fr) 1999-04-07
CN1074922C (zh) 2001-11-21
ATE178489T1 (de) 1999-04-15
NO963244L (no) 1996-08-02
DE69508924T2 (de) 1999-10-21
SK281214B6 (sk) 2001-01-18
AP536A (en) 1996-09-26
AP611A (en) 1997-09-03
CZ285128B6 (cs) 1999-05-12
MY113036A (en) 2001-11-30
GR3030131T3 (en) 1999-07-30
WO1995020964A1 (fr) 1995-08-10
HUT75941A (en) 1997-05-28
JPH09508402A (ja) 1997-08-26
NO963244D0 (no) 1996-08-02
OA10446A (en) 2002-03-26
FI963051A0 (fi) 1996-08-01
RU2136281C1 (ru) 1999-09-10
NO307954B1 (no) 2000-06-26
AP9500715A0 (en) 1995-04-30
HK1012288A1 (en) 1999-07-30
GB9402029D0 (en) 1994-03-30
EP0742715A1 (fr) 1996-11-20
BG62843B1 (bg) 2000-09-29
FI118205B (fi) 2007-08-31
TW436296B (en) 2001-05-28
SK100496A3 (en) 1996-12-04
RO116342B1 (ro) 2001-01-30
JP4445590B2 (ja) 2010-04-07
AP9600839A0 (en) 1996-07-31
FI963051L (fi) 1996-08-01
PL315679A1 (en) 1996-11-25
DK0742715T3 (da) 1999-10-18
ES2129806T3 (es) 1999-06-16
IL112521A (en) 1999-09-22
CA2182593A1 (fr) 1995-08-10
CZ229396A3 (en) 1997-01-15
ZA95776B (en) 1996-08-01
US5811436A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
DZ1850A1 (fr) Formulation nouvelle comprenant un complexe de paroxétine et d'amberlite irp 88.
EP0708355A3 (fr) Dispositif d'affichage
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
EP1014257A4 (fr) Dispositif d'affichage a fenetres
BR9502666A (pt) Eixo articulado
NO308131B1 (no) Hypolipidemiske 1,4-benzotiazepin-1,1-dioksider, anvendelse derav og farmasøytisk blanding
NZ329932A (en) Hypolipidemic 1,4-benzothiazepine-1,1-dioxides and pharmaceutical compositions thereof
EP0949603A4 (fr) Dispositif d'affichage
EP0667727A3 (fr) Dispositif d'interface.
EP0863495A4 (fr) Dispositif d'affichage
FI962751A7 (fi) Uusia hydroksyyliryhmän sisältäviä 1,3-dialkyyliureajohdannaisia
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
ZA958606B (en) A pharmaceutical formulation
EP0708273A3 (fr) Mécanisme d'entraînement
EP0689086A3 (fr) Dispositif d'affichage
GB9815170D0 (en) 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7YL)butanoyl-glycyl-3(S)-Quinolin-3- YL-B-alanine and salts thereof
FR2748146B1 (fr) Dispositif d'affichage
FR2718999B1 (fr) Dispositif d'attelage auxiliaire.
FR2753208B1 (fr) Dispositif d'aiguilletage d'un matelas prefixe
FR2736379B1 (fr) Dispositif d'articulation
FR2730974B1 (fr) Dispositif d'entrainement
ITRM940387A0 (it) "giunto a tampone viscoelastico anidro".
FR2744917B1 (fr) Composition therapeutique a base d'acetaminophene
FR2728455B1 (fr) Dispositif d'osteosynthese
FR2724751B3 (fr) Dispositif d'identification